RU2018126315A3 - - Google Patents

Info

Publication number: RU2018126315A3
Authority: RU; Russia

Application number

RU2018126315A

Other versions

RU2018126315A (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-18

Filing date

2016-12-14

Publication date

2020-04-30

2016-12-14 Application filed filed Critical

2020-01-20 Publication of RU2018126315A publication Critical patent/RU2018126315A/ru

2020-04-30 Publication of RU2018126315A3 publication Critical patent/RU2018126315A3/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

RU2018126315A 2015-12-18 2016-12-14 Молекулы антител, которые связываются с tnf-альфа RU2018126315A (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB1522394.4		2015-12-18
GBGB1522394.4A GB201522394D0 (en)	2015-12-18	2015-12-18	Antibodies
PCT/EP2016/080984 WO2017102833A1 (en)	2015-12-18	2016-12-14	Antibody molecules which bind tnf alpha

Publications (2)

Publication Number	Publication Date
RU2018126315A RU2018126315A (ru)	2020-01-20
RU2018126315A3 true RU2018126315A3 (ru)	2020-04-30

Family

ID=55311230

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2018126315A RU2018126315A (ru)	2015-12-18	2016-12-14	Молекулы антител, которые связываются с tnf-альфа

Country Status (18)

Country	Link
US (1)	US11091542B2 (ru)
EP (1)	EP3390446A1 (ru)
JP (1)	JP7082053B2 (ru)
KR (1)	KR20180089521A (ru)
CN (1)	CN108368168B (ru)
AR (1)	AR107071A1 (ru)
AU (1)	AU2016374375A1 (ru)
BR (1)	BR112018011862A2 (ru)
CA (1)	CA3007580A1 (ru)
CL (1)	CL2018001661A1 (ru)
CO (1)	CO2018006555A2 (ru)
EA (1)	EA036904B1 (ru)
GB (1)	GB201522394D0 (ru)
IL (1)	IL259883A (ru)
MX (1)	MX2018007221A (ru)
RU (1)	RU2018126315A (ru)
SG (1)	SG11201804801SA (ru)
WO (1)	WO2017102833A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114144431B (zh) *	2019-08-08	2023-04-14	神州细胞工程有限公司	人源化抗TNFα抗体及其用途
GB201919062D0 (en) *	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt)	1989-01-24	1990-07-31		Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en)	1991-03-18	2001-09-04	New York University Medical Center	Anti-TNFa antibodies and assays employing anti-TNFa antibodies
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
FR2716640B1 (fr)	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
WO1996033204A1 (en)	1995-04-20	1996-10-24	The Kennedy Institute Of Rheumatology	Multiple administrations of anti-tnf antibody
CN103275221B (zh)	1996-02-09	2016-08-17	艾伯维生物技术有限公司	结合人TNFα的人抗体
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
GB0013810D0 (en)	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
UA81743C2 (ru)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ЧЕЛОВЕКА, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С ФАКТОРОМ НЕКРОЗА ОПУХОЛЕЙ АЛЬФА (ФНПα), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ РЕВМАТОИДНОГО АРТРИТА
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en)	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
WO2003083061A2 (en)	2002-03-26	2003-10-09	Centocor, Inc.	Anti-tnf antibodies, compositions, methods and uses
AU2003285578B2 (en)	2002-12-03	2010-07-15	Ucb Pharma S.A.	Assay for identifying antibody producing cells
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
DK1644412T4 (en)	2003-07-01	2018-11-12	Ucb Biopharma Sprl	MODIFIED ANTIBODY-FAB FRAGMENTS
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
TWI439284B (zh) *	2004-04-09	2014-06-01	Abbvie Biotechnology Ltd	用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
GB0425972D0 (en) *	2004-11-25	2004-12-29	Celltech R&D Ltd	Biological products
EP2479191A3 (en) *	2005-05-18	2013-03-13	Ablynx N.V.	Improved nanobodiesTM against tumor necrosis factor-alpha
CA2618482C (en)	2005-08-19	2014-10-07	Abbott Laboratories	Dual variable domain immunoglobin and uses thereof
WO2007060411A1 (en)	2005-11-24	2007-05-31	Ucb Pharma S.A.	Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
GB0619291D0 (en)	2006-09-29	2006-11-08	Ucb Sa	Altered antibodies
US9056905B2 (en) *	2007-05-21	2015-06-16	Alderbio Holdings Llc	Antibodies to TNF-α and use thereof
NZ581418A (en) *	2007-05-21	2012-08-31	Alderbio Holdings Llc	Novel rabbit antibody humanization methods and humanized rabbit antibodies
EP2195341B1 (en)	2007-09-26	2017-03-22	UCB Biopharma SPRL	Dual specificity antibody fusions
CA2727992C (en)	2008-06-25	2017-10-17	Esbatech, An Alcon Biomedical Research Unit Llc	Stable and soluble antibodies inhibiting tnf.alpha.
LT2334705T (lt)	2008-09-26	2017-03-27	Ucb Biopharma Sprl	Biologiniai produktai
HUE031756T2 (en) *	2008-10-31	2017-07-28	Janssen Biotech Inc	TLR3 antagonists
SG175181A1 (en)	2009-04-16	2011-11-28	Abbott Biotherapeutics Corp	ANTI-TNF-a ANTIBODIES AND THEIR USES
WO2011030107A1 (en)	2009-09-10	2011-03-17	Ucb Pharma S.A.	Multivalent antibodies
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
CL2010000019A1 (es)	2010-01-11	2010-06-11	Univ Chile	Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
CA2805572A1 (en)	2010-07-16	2012-01-19	Martin Hegen	Modified single domain antigen binding molecules and uses thereof
AR083495A1 (es)	2010-10-22	2013-02-27	Esbatech Alcon Biomed Res Unit	Anticuerpos estables y solubles
SG191712A1 (en)	2010-11-02	2013-08-30	Abbvie Inc	Dual variable domain immunoglobulins and uses thereof
AR084210A1 (es)	2010-12-08	2013-05-02	Abbott Lab	PROTEINAS DE UNION AL TNF-a
GB201106395D0 (en) *	2011-04-14	2011-06-01	Hubrecht Inst	Compounds
GB201112429D0 (en)	2011-07-19	2011-08-31	Glaxo Group Ltd	Antigen-binding proteins with increased FcRn binding
US9395071B2 (en)	2011-09-06	2016-07-19	Koninklijke Philips N.V.	Wire-based lighting module with 3D topography
AU2012328921B2 (en)	2011-10-24	2017-05-11	Abbvie Inc.	Immunobinders directed against TNF
JP6121432B2 (ja)	2011-10-24	2017-04-26	アッヴィ・インコーポレイテッド	Ｔｎｆおよびｉｌ−１７に対する双特異性免疫結合剤
TR201807207T4 (tr)	2012-06-11	2018-06-21	Ucb Biopharma Sprl	Tnf-alfa modüle edici benzimidazol bileşikleri.
JP2016517277A (ja)	2013-03-15	2016-06-16	アッヴィ・インコーポレイテッド	ＴＮＦαに対して指向された二重特異的結合タンパク質
WO2015144852A1 (en) *	2014-03-26	2015-10-01	Delenex Therapeutics Ag	Binding members to tnf alpha
GB201411320D0 (en)	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
AP2017009776A0 (en)	2014-09-03	2017-02-28	Boehringer Ingelheim Int	Compound targeting il-23a and tnf-alpha and uses thereof
GB201510758D0 (en)	2015-06-18	2015-08-05	Ucb Biopharma Sprl	Novel TNFa structure for use in therapy
NO2768984T3 (ru)	2015-11-12	2018-06-09
CR20180365A (es)	2015-12-16	2018-09-28	Amgen Inc	PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
GB201522391D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibody molecules

2015
- 2015-12-18 GB GBGB1522394.4A patent/GB201522394D0/en not_active Ceased
2016
- 2016-12-14 MX MX2018007221A patent/MX2018007221A/es unknown
- 2016-12-14 RU RU2018126315A patent/RU2018126315A/ru not_active Application Discontinuation
- 2016-12-14 EA EA201891445A patent/EA036904B1/ru unknown
- 2016-12-14 BR BR112018011862A patent/BR112018011862A2/pt not_active IP Right Cessation
- 2016-12-14 KR KR1020187020777A patent/KR20180089521A/ko not_active Withdrawn
- 2016-12-14 JP JP2018531425A patent/JP7082053B2/ja active Active
- 2016-12-14 AU AU2016374375A patent/AU2016374375A1/en not_active Abandoned
- 2016-12-14 WO PCT/EP2016/080984 patent/WO2017102833A1/en not_active Ceased
- 2016-12-14 SG SG11201804801SA patent/SG11201804801SA/en unknown
- 2016-12-14 EP EP16822625.6A patent/EP3390446A1/en active Pending
- 2016-12-14 CN CN201680073700.0A patent/CN108368168B/zh not_active Expired - Fee Related
- 2016-12-14 CA CA3007580A patent/CA3007580A1/en active Pending
- 2016-12-14 US US16/063,133 patent/US11091542B2/en active Active
- 2016-12-16 AR ARP160103879A patent/AR107071A1/es active IP Right Grant
2018
- 2018-06-07 IL IL259883A patent/IL259883A/en unknown
- 2018-06-18 CL CL2018001661A patent/CL2018001661A1/es unknown
- 2018-06-26 CO CONC2018/0006555A patent/CO2018006555A2/es unknown

Also Published As

Publication number	Publication date
JP2019508367A (ja)	2019-03-28
RU2018126315A (ru)	2020-01-20
EP3390446A1 (en)	2018-10-24
MX2018007221A (es)	2018-08-01
KR20180089521A (ko)	2018-08-08
US11091542B2 (en)	2021-08-17
JP7082053B2 (ja)	2022-06-07
EA036904B1 (ru)	2021-01-13
SG11201804801SA (en)	2018-07-30
CA3007580A1 (en)	2017-06-22
BR112018011862A2 (pt)	2018-12-04
CN108368168B (zh)	2022-03-01
GB201522394D0 (en)	2016-02-03
IL259883A (en)	2018-07-31
CL2018001661A1 (es)	2018-10-19
AU2016374375A8 (en)	2018-07-05
AR107071A1 (es)	2018-03-14
WO2017102833A1 (en)	2017-06-22
CO2018006555A2 (es)	2018-07-10
EA201891445A1 (ru)	2018-11-30
CN108368168A (zh)	2018-08-03
US20200291104A1 (en)	2020-09-17
AU2016374375A1 (en)	2018-06-28

Publication	Publication Date	Title
RU2018126315A3 (ru)	2020-04-30
AU2022228198B1 (ru)	2025-09-11
BE2015C047I2 (ru)	2022-08-10
CN303074403S (ru)	2015-01-14
BR0002402B1 (ru)	2015-08-11
BR0000126B1 (ru)	2015-07-14
BR0000695B1 (ru)	2015-07-21
BR0000763F1 (ru)	2015-09-15
BR0001536B1 (ru)	2015-09-29
BR0001684B1 (ru)	2015-04-22
BR0001810B1 (ru)	2015-06-23
BR0002033B1 (ru)	2015-06-09
BR0002435B1 (ru)	2015-05-19
BR0002694B1 (ru)	2015-08-04
BR0002802B1 (ru)	2015-03-31
BR0002874B1 (ru)	2015-09-01
BR0003166B1 (ru)	2015-08-25
BR0003208B1 (ru)	2015-03-17
BR0003401B1 (ru)	2015-08-25
BR0003686B1 (ru)	2015-08-18
BR0003746B1 (ru)	2015-08-25
BR0003751B1 (ru)	2015-08-11
BR0003928B1 (ru)	2015-09-15
BR0004687B1 (ru)	2015-05-05
BR0005041B1 (ru)	2015-08-11

Legal Events

Date	Code	Title	Description
2020-11-10	FA92	Acknowledgement of application withdrawn (lack of supplementary materials submitted)	Effective date: 20201029